CRISPR Therapeutics AG (CRSP) Operating Expenses (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Operating Expenses data on file, last reported at $131.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 11.78% year-over-year to $131.7 million; the trailing twelve-month figure through Mar 2026 stood at $650.5 million (up 27.03% YoY), and the FY2025 full-year result was $668.1 million, up 32.59% from the prior year.
• Operating Expenses retreated to $131.7 million in Q1 2026, from $155.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $230.2 million in Q2 2025 to a low of $100.3 million in Q4 2024.
• A 5-year average of $151.3 million and a median of $149.3 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 27.44% in 2023 and surged 55.2% in 2025, its largest moves.
• Tracing CRSP's Operating Expenses over 5 years: stood at $131.5 million in 2022, then grew by 0.06% to $131.6 million in 2023, then fell by 23.81% to $100.3 million in 2024, then surged by 55.2% to $155.6 million in 2025, then declined by 15.37% to $131.7 million in 2026.
• Business Quant data shows CRSP's Operating Expenses at $131.7 million in Q1 2026, $155.6 million in Q4 2025, and $132.9 million in Q3 2025.